Stifel analyst Bradley Canino raised the firm’s price target on Affimed to $5 from $1 and keeps a Hold rating on the shares following the recent stock split. Affimed narrowed program updates to Q2 during Friday’s call, saying enrollment for cohorts 3 and 4 for acimtamig+AB-101will begin mid-April, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
